T
1.08
0.02 (2.38%)
| Previous Close | 1.05 |
| Open | 1.05 |
| Volume | 70,788 |
| Avg. Volume (3M) | 185,603 |
| Market Cap | 55,798,732 |
| Price / Sales | 78.80 |
| Price / Book | 4.47 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2026 |
| Operating Margin (TTM) | -10,800.00% |
| Diluted EPS (TTM) | -0.440 |
| Total Debt/Equity (MRQ) | 116.57% |
| Current Ratio (MRQ) | 3.11 |
| Operating Cash Flow (TTM) | -13.27 M |
| Levered Free Cash Flow (TTM) | -8.73 M |
| Return on Assets (TTM) | -39.79% |
| Return on Equity (TTM) | -106.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Talphera, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.3 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | -1.5 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.15 |
Select this tab to load the latest available analysis.
|
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 31.31% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |